Molecular Cancer Therapeutics · 2018 · 62 citations · 30 references
MedicineCancer BiologyOncologyMolecular OncologyNeuro-oncologyPediatric OncologyBrain TumorsCancer Stem CellsPediatric Brain TumorsTelomere BiologyTelomere Biology In CancerTelomere DysfunctionCancer Stem-like CellsPediatric High-grade GliomaTelomerase ActivationTelomerase FunctionTelomere Dna Damage ResponseTelomere Dysfunction In CancerTelomere Dysfunction-induced FociTelomere Function
Abstract Brain tumors remain the leading cause of cancer-related deaths in children and often are associated with long-term sequelae among survivors of current therapies. Hence, there is an urgent need to identify actionable targets and to develop more effective therapies. Telomerase and telomeres play important roles in cancer, representing attractive therapeutic targets to treat children with poor-prognosis brain tumors such as diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. We have previously shown that DIPG, HGG, and medulloblastoma frequently express telomerase activity. Here, we show that the telomerase-dependent incorporation of 6-thio-2′deoxyguanosine (6-thio-dG), a telomerase substrate precursor analogue, into telomeres leads to telomere dysfunction–induced foci (TIF) along with extensive genomic DNA damage, cell growth inhibition, and cell death of primary stem-like cells derived from patients with DIPG, HGG, and medulloblastoma. Importantly, the effect of 6-thio-dG is persistent even after drug withdrawal. Treatment with 6-thio-dG elicits a sequential activation of ATR and ATM pathways and induces G2–M arrest. In vivo treatment of mice bearing medulloblastoma xenografts with 6-thio-dG delays tumor growth and increases in-tumor TIFs and apoptosis. Furthermore, 6-thio-dG crosses the blood–brain barrier and specifically targets tumor cells in an orthotopic mouse model of DIPG. Together, our findings suggest that 6-thio-dG is a promising novel approach to treat therapy-resistant telomerase-positive pediatric brain tumors. Mol Cancer Ther; 17(7); 1504–14. ©2018 AACR.
30
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Nam W. Kim, Mieczyslaw A. Piatyszek, Karen R. Prowse et al. · Science · 1994 · 7.1K citations
A DNA damage checkpoint response in telomere-initiated senescence
Fabrizio d’Adda di Fagagna, Philip M. Reaper, Lorena Clay-Farrace et al. · Nature · 2003 · 2.8K citations
DNA Damage Foci at Dysfunctional Telomeres
Hiroyuki Takai, Agata Smogorzewska, Titia de Lange · Current Biology · 2003 · 1.4K citations · Full text